Enoxaparin - a low-molecular-weight heparin

Article Abstract:

Rhone-Poulenc Rorer's Lovenox (enoxaparin) is a low-molecular-weight heparin that the US Food and Drug Administration (FDA) has approved for use as a treatment for deep vein thrombosis after hip replacement surgery. Heparin is an anti-coagulant that can prevent or reduce blood clots. Deep vein thrombosis is a clot that develops most frequently in the femoral or iliac arteries about half the time after orthopedic surgery if no anti-coagulants are used. Low-molecular-weight heparin is a derivative of standard heparin; it has a greater proportion of the chemical factors that prevent excessive clotting. Several low-molecular-weight heparins have been tested on patients with strokes and spinal cord injuries and on older patients at high risk for thrombosis. They vary in their effectiveness, but some, such as enoxaparin, appear to be as effective and safe as standard heparin. Low doses of heparin injected subcutaneously may be even safer.

Product development, Anticoagulants (Medicine), Anticoagulants, Licensing agreements, Lovenox (Medication)

---

Ardeparin and danaparoid for prevention of deep vein thrombosis

Article Abstract:

Ardeparin sodium and danaparoid sodium appear to be slightly better at preventing blood clots after knee and hip surgery than warfarin or standard heparin. Ardeparin is a low-molecular-weight heparin and danaparoid is a heparinoid. Clinical trials showed ardeparin twice as effective at preventing thrombosis after knee surgery than placebos and 12% more effective than warfarin. Treatment with danaparoid was seen to improve prevention of clots after hip replacement over standard heparin treatment. Both drugs produce predictable blood levels and do not require the constant monitoring needed with standard heparin treatment.

Prevention

---

Tinzaparin, a low molecular weight heparin for treatment of deep vein thrombosis

Article Abstract:

The FDA has approved tinzaparin for the treatment of deep vein thrombosis. Sold under the trade name Innohep, it is as safe and effective as regular heparin. Deep vein thrombosis occurs when a blood clot forms in the large veins in the legs.

Product/Service Evaluation, Product information, DuPont Pharmaceuticals, Innohep (Medication)

Similar abstracts:

• Abstracts: Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement
• Abstracts: HIV risk perception and prevalence in a program for prevention of mother-to-child HIV transmission. Effects of lipolysis or heat treatment on HIV-1 provirus in breast milk
• Abstracts: PET of brain amyloid and tau in mild cognitive impairment. Visualizing out-of-body experience in the brain. Patterns of brain activation in people at risk for Alzheimer's disease
• Abstracts: Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. Relapse, remission, and progression in multiple sclerosis
• Abstracts: Reperfusion and revascularization strategies for coronary artery disease in women. Choice of Revascularization Strategy for Patients With Coronary Artery Disease

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.